nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—PGR—multiple sclerosis	0.336	1	CbGaD
Levonorgestrel—PGR—Betamethasone—multiple sclerosis	0.086	0.316	CbGbCtD
Levonorgestrel—PGR—Dexamethasone—multiple sclerosis	0.0501	0.184	CbGbCtD
Levonorgestrel—CYP19A1—Betamethasone—multiple sclerosis	0.0484	0.178	CbGbCtD
Levonorgestrel—Danazol—Prednisone—multiple sclerosis	0.0368	0.133	CrCrCtD
Levonorgestrel—CYP19A1—Dexamethasone—multiple sclerosis	0.0282	0.103	CbGbCtD
Levonorgestrel—Progesterone—Prednisolone—multiple sclerosis	0.0263	0.0953	CrCrCtD
Levonorgestrel—Methyltestosterone—Prednisone—multiple sclerosis	0.0263	0.0952	CrCrCtD
Levonorgestrel—Methyltestosterone—Prednisolone—multiple sclerosis	0.0257	0.0929	CrCrCtD
Levonorgestrel—Hydrocortisone—Methylprednisolone—multiple sclerosis	0.0241	0.0873	CrCrCtD
Levonorgestrel—Hydrocortisone—Betamethasone—multiple sclerosis	0.0237	0.0859	CrCrCtD
Levonorgestrel—Hydrocortisone—Dexamethasone—multiple sclerosis	0.0237	0.0859	CrCrCtD
Levonorgestrel—Hydrocortisone—Triamcinolone—multiple sclerosis	0.0232	0.0839	CrCrCtD
Levonorgestrel—Testosterone—Prednisolone—multiple sclerosis	0.0229	0.0828	CrCrCtD
Levonorgestrel—Hydrocortisone—Prednisone—multiple sclerosis	0.022	0.0797	CrCrCtD
Levonorgestrel—Hydrocortisone—Prednisolone—multiple sclerosis	0.0215	0.0777	CrCrCtD
Levonorgestrel—CYP3A4—Fingolimod—multiple sclerosis	0.0146	0.0538	CbGbCtD
Levonorgestrel—CYP3A4—Methylprednisolone—multiple sclerosis	0.00943	0.0346	CbGbCtD
Levonorgestrel—CYP3A4—Triamcinolone—multiple sclerosis	0.00715	0.0263	CbGbCtD
Levonorgestrel—CYP3A4—Mitoxantrone—multiple sclerosis	0.00688	0.0253	CbGbCtD
Levonorgestrel—CYP3A4—Betamethasone—multiple sclerosis	0.00613	0.0225	CbGbCtD
Levonorgestrel—CYP3A4—Prednisolone—multiple sclerosis	0.00605	0.0222	CbGbCtD
Levonorgestrel—CYP3A4—Prednisone—multiple sclerosis	0.00571	0.021	CbGbCtD
Levonorgestrel—CYP3A4—Dexamethasone—multiple sclerosis	0.00357	0.0131	CbGbCtD
Levonorgestrel—Ethynodiol—PGR—multiple sclerosis	0.000458	0.132	CrCbGaD
Levonorgestrel—Allylestrenol—PGR—multiple sclerosis	0.000433	0.124	CrCbGaD
Levonorgestrel—Norelgestromin—PGR—multiple sclerosis	0.000433	0.124	CrCbGaD
Levonorgestrel—Desogestrel—PGR—multiple sclerosis	0.000417	0.12	CrCbGaD
Levonorgestrel—Norgestimate—PGR—multiple sclerosis	0.00039	0.112	CrCbGaD
Levonorgestrel—Danazol—CCL2—multiple sclerosis	0.000357	0.102	CrCbGaD
Levonorgestrel—Etonogestrel—PGR—multiple sclerosis	0.000337	0.0968	CrCbGaD
Levonorgestrel—Danazol—PGR—multiple sclerosis	0.000217	0.0624	CrCbGaD
Levonorgestrel—Norethindrone—PGR—multiple sclerosis	0.000193	0.0555	CrCbGaD
Levonorgestrel—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000164	0.005	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—ZMIZ1—multiple sclerosis	0.000163	0.00499	CbGpPWpGaD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—PGR—multiple sclerosis	0.00016	0.00489	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—IFNB1—multiple sclerosis	0.000152	0.00463	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—ZMIZ1—multiple sclerosis	0.000146	0.00447	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of steroid hormones and vitamin D—POMC—multiple sclerosis	0.000146	0.00446	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.000143	0.00436	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.00014	0.00429	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.00014	0.00429	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CYP27B1—multiple sclerosis	0.000136	0.00417	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CYP24A1—multiple sclerosis	0.000136	0.00417	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.000134	0.0041	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000133	0.00407	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—CD28—multiple sclerosis	0.000133	0.00405	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—GPC5—multiple sclerosis	0.000125	0.00381	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—VDR—multiple sclerosis	0.00012	0.00368	CbGpPWpGaD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000117	0.00359	CbGpPWpGaD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000117	0.00359	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—IL10—multiple sclerosis	0.000117	0.00358	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—IFNB1—multiple sclerosis	0.000117	0.00357	CbGpPWpGaD
Levonorgestrel—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000116	0.00354	CbGpPWpGaD
Levonorgestrel—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000116	0.00354	CbGpPWpGaD
Levonorgestrel—Progesterone—PGR—multiple sclerosis	0.000113	0.0323	CrCbGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.00011	0.00336	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000108	0.0033	CbGpPWpGaD
Levonorgestrel—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000105	0.00322	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—RRM1—multiple sclerosis	0.000103	0.00316	CbGpPWpGaD
Levonorgestrel—AR—Notch-mediated HES/HEY network—CD4—multiple sclerosis	0.000103	0.00314	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL10—multiple sclerosis	0.000101	0.0031	CbGpPWpGaD
Levonorgestrel—AR—Nongenotropic Androgen signaling—MAPK1—multiple sclerosis	0.000101	0.00308	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—MAPK1—multiple sclerosis	9.86e-05	0.00301	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL4—multiple sclerosis	9.85e-05	0.00301	CbGpPWpGaD
Levonorgestrel—CYP19A1—FSH signaling pathway—MAPK1—multiple sclerosis	9.69e-05	0.00296	CbGpPWpGaD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	9.52e-05	0.00291	CbGpPWpGaD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	9.52e-05	0.00291	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—CD86—multiple sclerosis	9.47e-05	0.00289	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—multiple sclerosis	9.27e-05	0.00283	CbGpPWpGaD
Levonorgestrel—CYP19A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.05e-05	0.00276	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ZNF746—multiple sclerosis	9.02e-05	0.00276	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—multiple sclerosis	9.01e-05	0.00275	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—HLA-A—multiple sclerosis	8.93e-05	0.00273	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—PTBP1—multiple sclerosis	8.25e-05	0.00252	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.02e-05	0.00245	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PGR—multiple sclerosis	8.01e-05	0.00245	CbGpPWpGaD
Levonorgestrel—AR—Notch-mediated HES/HEY network—STAT3—multiple sclerosis	7.95e-05	0.00243	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—CD28—multiple sclerosis	7.79e-05	0.00238	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	7.69e-05	0.00235	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—MMP9—multiple sclerosis	7.69e-05	0.00235	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—MYC—multiple sclerosis	7.58e-05	0.00232	CbGpPWpGaD
Levonorgestrel—CYP19A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.33e-05	0.00224	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	7.31e-05	0.000924	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Methotrexate—multiple sclerosis	7.28e-05	0.00092	CcSEcCtD
Levonorgestrel—Loss of consciousness—Triamcinolone—multiple sclerosis	7.26e-05	0.000918	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	7.26e-05	0.00222	CbGpPWpGaD
Levonorgestrel—Loss of consciousness—Methylprednisolone—multiple sclerosis	7.24e-05	0.000916	CcSEcCtD
Levonorgestrel—Shock—Prednisolone—multiple sclerosis	7.21e-05	0.000912	CcSEcCtD
Levonorgestrel—Cough—Triamcinolone—multiple sclerosis	7.21e-05	0.000911	CcSEcCtD
Levonorgestrel—Hypertension—Triamcinolone—multiple sclerosis	7.13e-05	0.000901	CcSEcCtD
Levonorgestrel—Hypertension—Methylprednisolone—multiple sclerosis	7.11e-05	0.000899	CcSEcCtD
Levonorgestrel—Urticaria—Mitoxantrone—multiple sclerosis	7.1e-05	0.000897	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Prednisolone—multiple sclerosis	7.09e-05	0.000896	CcSEcCtD
Levonorgestrel—Abdominal pain—Mitoxantrone—multiple sclerosis	7.06e-05	0.000893	CcSEcCtD
Levonorgestrel—Body temperature increased—Mitoxantrone—multiple sclerosis	7.06e-05	0.000893	CcSEcCtD
Levonorgestrel—Myalgia—Triamcinolone—multiple sclerosis	7.03e-05	0.000889	CcSEcCtD
Levonorgestrel—Vomiting—Azathioprine—multiple sclerosis	7.03e-05	0.000888	CcSEcCtD
Levonorgestrel—Pneumonia—Methotrexate—multiple sclerosis	7.02e-05	0.000887	CcSEcCtD
Levonorgestrel—Myalgia—Methylprednisolone—multiple sclerosis	7.02e-05	0.000887	CcSEcCtD
Levonorgestrel—Eye disorder—Prednisone—multiple sclerosis	7.01e-05	0.000886	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CCL2—multiple sclerosis	7.01e-05	0.00214	CbGpPWpGaD
Levonorgestrel—Anxiety—Methylprednisolone—multiple sclerosis	6.99e-05	0.000884	CcSEcCtD
Levonorgestrel—Infestation NOS—Methotrexate—multiple sclerosis	6.98e-05	0.000882	CcSEcCtD
Levonorgestrel—Infestation—Methotrexate—multiple sclerosis	6.98e-05	0.000882	CcSEcCtD
Levonorgestrel—Rash—Azathioprine—multiple sclerosis	6.97e-05	0.000881	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	6.97e-05	0.000881	CcSEcCtD
Levonorgestrel—Dermatitis—Azathioprine—multiple sclerosis	6.96e-05	0.00088	CcSEcCtD
Levonorgestrel—Depression—Methotrexate—multiple sclerosis	6.96e-05	0.00088	CcSEcCtD
Levonorgestrel—Discomfort—Triamcinolone—multiple sclerosis	6.95e-05	0.000878	CcSEcCtD
Levonorgestrel—Discomfort—Methylprednisolone—multiple sclerosis	6.93e-05	0.000876	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL10—multiple sclerosis	6.93e-05	0.00212	CbGpPWpGaD
Levonorgestrel—Headache—Azathioprine—multiple sclerosis	6.92e-05	0.000875	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—CD80—multiple sclerosis	6.91e-05	0.00211	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.89e-05	0.00211	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ZNF746—multiple sclerosis	6.87e-05	0.0021	CbGpPWpGaD
Levonorgestrel—Angioedema—Dexamethasone—multiple sclerosis	6.85e-05	0.000866	CcSEcCtD
Levonorgestrel—Angioedema—Betamethasone—multiple sclerosis	6.85e-05	0.000866	CcSEcCtD
Levonorgestrel—ESR1—ATF-2 transcription factor network—IFNG—multiple sclerosis	6.83e-05	0.00209	CbGpPWpGaD
Levonorgestrel—Immune system disorder—Prednisone—multiple sclerosis	6.77e-05	0.000856	CcSEcCtD
Levonorgestrel—Oedema—Triamcinolone—multiple sclerosis	6.74e-05	0.000852	CcSEcCtD
Levonorgestrel—Vertigo—Dexamethasone—multiple sclerosis	6.73e-05	0.000851	CcSEcCtD
Levonorgestrel—Vertigo—Betamethasone—multiple sclerosis	6.73e-05	0.000851	CcSEcCtD
Levonorgestrel—Syncope—Dexamethasone—multiple sclerosis	6.72e-05	0.00085	CcSEcCtD
Levonorgestrel—Syncope—Betamethasone—multiple sclerosis	6.72e-05	0.00085	CcSEcCtD
Levonorgestrel—Arrhythmia—Prednisone—multiple sclerosis	6.7e-05	0.000847	CcSEcCtD
Levonorgestrel—Infection—Triamcinolone—multiple sclerosis	6.7e-05	0.000847	CcSEcCtD
Levonorgestrel—Infection—Methylprednisolone—multiple sclerosis	6.68e-05	0.000845	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.65e-05	0.00203	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.65e-05	0.00203	CbGpPWpGaD
Levonorgestrel—Shock—Triamcinolone—multiple sclerosis	6.63e-05	0.000838	CcSEcCtD
Levonorgestrel—Insomnia—Prednisolone—multiple sclerosis	6.63e-05	0.000838	CcSEcCtD
Levonorgestrel—Alopecia—Prednisone—multiple sclerosis	6.63e-05	0.000838	CcSEcCtD
Levonorgestrel—Shock—Methylprednisolone—multiple sclerosis	6.62e-05	0.000836	CcSEcCtD
Levonorgestrel—Nervous system disorder—Methylprednisolone—multiple sclerosis	6.6e-05	0.000834	CcSEcCtD
Levonorgestrel—Loss of consciousness—Betamethasone—multiple sclerosis	6.59e-05	0.000833	CcSEcCtD
Levonorgestrel—Loss of consciousness—Dexamethasone—multiple sclerosis	6.59e-05	0.000833	CcSEcCtD
Levonorgestrel—Hypersensitivity—Mitoxantrone—multiple sclerosis	6.58e-05	0.000832	CcSEcCtD
Levonorgestrel—Mental disorder—Prednisone—multiple sclerosis	6.57e-05	0.00083	CcSEcCtD
Levonorgestrel—Nausea—Azathioprine—multiple sclerosis	6.56e-05	0.00083	CcSEcCtD
Levonorgestrel—Skin disorder—Methylprednisolone—multiple sclerosis	6.53e-05	0.000826	CcSEcCtD
Levonorgestrel—Erythema—Prednisone—multiple sclerosis	6.53e-05	0.000825	CcSEcCtD
Levonorgestrel—Malnutrition—Prednisone—multiple sclerosis	6.53e-05	0.000825	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Triamcinolone—multiple sclerosis	6.52e-05	0.000824	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Methylprednisolone—multiple sclerosis	6.5e-05	0.000822	CcSEcCtD
Levonorgestrel—Hypertension—Dexamethasone—multiple sclerosis	6.47e-05	0.000818	CcSEcCtD
Levonorgestrel—Hypertension—Betamethasone—multiple sclerosis	6.47e-05	0.000818	CcSEcCtD
Levonorgestrel—Asthenia—Mitoxantrone—multiple sclerosis	6.41e-05	0.00081	CcSEcCtD
Levonorgestrel—Myalgia—Betamethasone—multiple sclerosis	6.38e-05	0.000807	CcSEcCtD
Levonorgestrel—Myalgia—Dexamethasone—multiple sclerosis	6.38e-05	0.000807	CcSEcCtD
Levonorgestrel—Anxiety—Betamethasone—multiple sclerosis	6.36e-05	0.000804	CcSEcCtD
Levonorgestrel—Anxiety—Dexamethasone—multiple sclerosis	6.36e-05	0.000804	CcSEcCtD
Levonorgestrel—Discomfort—Betamethasone—multiple sclerosis	6.3e-05	0.000797	CcSEcCtD
Levonorgestrel—Discomfort—Dexamethasone—multiple sclerosis	6.3e-05	0.000797	CcSEcCtD
Levonorgestrel—Haemoglobin—Methotrexate—multiple sclerosis	6.3e-05	0.000796	CcSEcCtD
Levonorgestrel—AR—Gene Expression—PTBP1—multiple sclerosis	6.28e-05	0.00192	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.28e-05	0.00192	CbGpPWpGaD
Levonorgestrel—Pain—Prednisolone—multiple sclerosis	6.27e-05	0.000792	CcSEcCtD
Levonorgestrel—Haemorrhage—Methotrexate—multiple sclerosis	6.27e-05	0.000792	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—U2AF2—multiple sclerosis	6.25e-05	0.00191	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—HNRNPA1—multiple sclerosis	6.25e-05	0.00191	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—MYC—multiple sclerosis	6.23e-05	0.0019	CbGpPWpGaD
Levonorgestrel—Pharyngitis—Methotrexate—multiple sclerosis	6.22e-05	0.000786	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Methotrexate—multiple sclerosis	6.19e-05	0.000782	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	6.17e-05	0.00189	CbGpPWpGaD
Levonorgestrel—Urethral disorder—Methotrexate—multiple sclerosis	6.14e-05	0.000776	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	6.14e-05	0.000776	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	6.13e-05	0.000775	CcSEcCtD
Levonorgestrel—Oedema—Betamethasone—multiple sclerosis	6.12e-05	0.000773	CcSEcCtD
Levonorgestrel—Oedema—Dexamethasone—multiple sclerosis	6.12e-05	0.000773	CcSEcCtD
Levonorgestrel—Diarrhoea—Mitoxantrone—multiple sclerosis	6.11e-05	0.000773	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—MYC—multiple sclerosis	6.11e-05	0.00187	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—IFNG—multiple sclerosis	6.1e-05	0.00186	CbGpPWpGaD
Levonorgestrel—Insomnia—Triamcinolone—multiple sclerosis	6.1e-05	0.000771	CcSEcCtD
Levonorgestrel—Insomnia—Methylprednisolone—multiple sclerosis	6.08e-05	0.000769	CcSEcCtD
Levonorgestrel—Infection—Dexamethasone—multiple sclerosis	6.08e-05	0.000768	CcSEcCtD
Levonorgestrel—Infection—Betamethasone—multiple sclerosis	6.08e-05	0.000768	CcSEcCtD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	6.05e-05	0.00185	CbGpPWpGaD
Levonorgestrel—Visual impairment—Methotrexate—multiple sclerosis	6.04e-05	0.000763	CcSEcCtD
Levonorgestrel—Anaemia—Prednisone—multiple sclerosis	6.03e-05	0.000763	CcSEcCtD
Levonorgestrel—Shock—Dexamethasone—multiple sclerosis	6.02e-05	0.000761	CcSEcCtD
Levonorgestrel—Shock—Betamethasone—multiple sclerosis	6.02e-05	0.000761	CcSEcCtD
Levonorgestrel—Dyspnoea—Triamcinolone—multiple sclerosis	6.01e-05	0.00076	CcSEcCtD
Levonorgestrel—Nervous system disorder—Dexamethasone—multiple sclerosis	6e-05	0.000758	CcSEcCtD
Levonorgestrel—Nervous system disorder—Betamethasone—multiple sclerosis	6e-05	0.000758	CcSEcCtD
Levonorgestrel—Angioedema—Prednisone—multiple sclerosis	5.96e-05	0.000754	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—IFNG—multiple sclerosis	5.96e-05	0.00182	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—BCHE—multiple sclerosis	5.94e-05	0.00181	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Triamcinolone—multiple sclerosis	5.93e-05	0.00075	CcSEcCtD
Levonorgestrel—Erythema multiforme—Methotrexate—multiple sclerosis	5.92e-05	0.000749	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	5.92e-05	0.00181	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Methylprednisolone—multiple sclerosis	5.92e-05	0.000748	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Dexamethasone—multiple sclerosis	5.91e-05	0.000747	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Betamethasone—multiple sclerosis	5.91e-05	0.000747	CcSEcCtD
Levonorgestrel—Vertigo—Prednisone—multiple sclerosis	5.86e-05	0.000741	CcSEcCtD
Levonorgestrel—Eye disorder—Methotrexate—multiple sclerosis	5.86e-05	0.00074	CcSEcCtD
Levonorgestrel—Syncope—Prednisone—multiple sclerosis	5.85e-05	0.00074	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—multiple sclerosis	5.84e-05	0.00179	CbGpPWpGaD
Levonorgestrel—Anorexia—Dexamethasone—multiple sclerosis	5.83e-05	0.000737	CcSEcCtD
Levonorgestrel—Anorexia—Betamethasone—multiple sclerosis	5.83e-05	0.000737	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—TYK2—multiple sclerosis	5.83e-05	0.00178	CbGpPWpGaD
Levonorgestrel—Urticaria—Prednisolone—multiple sclerosis	5.82e-05	0.000736	CcSEcCtD
Levonorgestrel—Cardiac disorder—Methotrexate—multiple sclerosis	5.82e-05	0.000735	CcSEcCtD
Levonorgestrel—Fatigue—Triamcinolone—multiple sclerosis	5.81e-05	0.000735	CcSEcCtD
Levonorgestrel—Fatigue—Methylprednisolone—multiple sclerosis	5.8e-05	0.000733	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	5.79e-05	0.00177	CbGpPWpGaD
Levonorgestrel—Pain—Triamcinolone—multiple sclerosis	5.76e-05	0.000729	CcSEcCtD
Levonorgestrel—Loss of consciousness—Prednisone—multiple sclerosis	5.74e-05	0.000725	CcSEcCtD
Levonorgestrel—Vomiting—Mitoxantrone—multiple sclerosis	5.68e-05	0.000718	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	5.67e-05	0.00173	CbGpPWpGaD
Levonorgestrel—Immune system disorder—Methotrexate—multiple sclerosis	5.66e-05	0.000715	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Methotrexate—multiple sclerosis	5.65e-05	0.000714	CcSEcCtD
Levonorgestrel—Hypertension—Prednisone—multiple sclerosis	5.63e-05	0.000712	CcSEcCtD
Levonorgestrel—Rash—Mitoxantrone—multiple sclerosis	5.63e-05	0.000712	CcSEcCtD
Levonorgestrel—Dermatitis—Mitoxantrone—multiple sclerosis	5.63e-05	0.000711	CcSEcCtD
Levonorgestrel—Headache—Mitoxantrone—multiple sclerosis	5.6e-05	0.000708	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	5.57e-05	0.000704	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	5.57e-05	0.000704	CcSEcCtD
Levonorgestrel—Myalgia—Prednisone—multiple sclerosis	5.56e-05	0.000702	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—CD86—multiple sclerosis	5.56e-05	0.0017	CbGpPWpGaD
Levonorgestrel—Anxiety—Prednisone—multiple sclerosis	5.54e-05	0.0007	CcSEcCtD
Levonorgestrel—Alopecia—Methotrexate—multiple sclerosis	5.54e-05	0.0007	CcSEcCtD
Levonorgestrel—Insomnia—Dexamethasone—multiple sclerosis	5.53e-05	0.000699	CcSEcCtD
Levonorgestrel—Insomnia—Betamethasone—multiple sclerosis	5.53e-05	0.000699	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	5.52e-05	0.000698	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	5.5e-05	0.000695	CcSEcCtD
Levonorgestrel—Discomfort—Prednisone—multiple sclerosis	5.49e-05	0.000694	CcSEcCtD
Levonorgestrel—Mental disorder—Methotrexate—multiple sclerosis	5.49e-05	0.000694	CcSEcCtD
Levonorgestrel—Malnutrition—Methotrexate—multiple sclerosis	5.45e-05	0.00069	CcSEcCtD
Levonorgestrel—Erythema—Methotrexate—multiple sclerosis	5.45e-05	0.00069	CcSEcCtD
Levonorgestrel—Norethindrone—ALB—multiple sclerosis	5.43e-05	0.0156	CrCbGaD
Levonorgestrel—ESR1—Regulation of Telomerase—IL2—multiple sclerosis	5.42e-05	0.00166	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Prednisolone—multiple sclerosis	5.4e-05	0.000683	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	5.39e-05	0.00165	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Betamethasone—multiple sclerosis	5.38e-05	0.000681	CcSEcCtD
Levonorgestrel—Dyspepsia—Dexamethasone—multiple sclerosis	5.38e-05	0.000681	CcSEcCtD
Levonorgestrel—Urticaria—Triamcinolone—multiple sclerosis	5.35e-05	0.000677	CcSEcCtD
Levonorgestrel—Urticaria—Methylprednisolone—multiple sclerosis	5.34e-05	0.000675	CcSEcCtD
Levonorgestrel—Body temperature increased—Triamcinolone—multiple sclerosis	5.33e-05	0.000674	CcSEcCtD
Levonorgestrel—Oedema—Prednisone—multiple sclerosis	5.33e-05	0.000673	CcSEcCtD
Levonorgestrel—Abdominal pain—Methylprednisolone—multiple sclerosis	5.32e-05	0.000672	CcSEcCtD
Levonorgestrel—Decreased appetite—Betamethasone—multiple sclerosis	5.32e-05	0.000672	CcSEcCtD
Levonorgestrel—Decreased appetite—Dexamethasone—multiple sclerosis	5.32e-05	0.000672	CcSEcCtD
Levonorgestrel—Nausea—Mitoxantrone—multiple sclerosis	5.31e-05	0.000671	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL2—multiple sclerosis	5.29e-05	0.00162	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—ZNF746—multiple sclerosis	5.29e-05	0.00162	CbGpPWpGaD
Levonorgestrel—Infection—Prednisone—multiple sclerosis	5.29e-05	0.000669	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	5.28e-05	0.00161	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	5.28e-05	0.000668	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Betamethasone—multiple sclerosis	5.28e-05	0.000668	CcSEcCtD
Levonorgestrel—Back pain—Methotrexate—multiple sclerosis	5.28e-05	0.000667	CcSEcCtD
Levonorgestrel—Fatigue—Betamethasone—multiple sclerosis	5.27e-05	0.000667	CcSEcCtD
Levonorgestrel—Fatigue—Dexamethasone—multiple sclerosis	5.27e-05	0.000667	CcSEcCtD
Levonorgestrel—Shock—Prednisone—multiple sclerosis	5.24e-05	0.000662	CcSEcCtD
Levonorgestrel—Pain—Dexamethasone—multiple sclerosis	5.23e-05	0.000661	CcSEcCtD
Levonorgestrel—Pain—Betamethasone—multiple sclerosis	5.23e-05	0.000661	CcSEcCtD
Levonorgestrel—Nervous system disorder—Prednisone—multiple sclerosis	5.22e-05	0.00066	CcSEcCtD
Levonorgestrel—Skin disorder—Prednisone—multiple sclerosis	5.17e-05	0.000654	CcSEcCtD
Levonorgestrel—Methyltestosterone—ALB—multiple sclerosis	5.16e-05	0.0148	CrCbGaD
Levonorgestrel—Hyperhidrosis—Prednisone—multiple sclerosis	5.15e-05	0.000651	CcSEcCtD
Levonorgestrel—Anorexia—Prednisone—multiple sclerosis	5.08e-05	0.000642	CcSEcCtD
Levonorgestrel—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	5.05e-05	0.00154	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	5.05e-05	0.00154	CbGpPWpGaD
Levonorgestrel—Anaemia—Methotrexate—multiple sclerosis	5.04e-05	0.000637	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—IL1B—multiple sclerosis	5.03e-05	0.00154	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—MMP9—multiple sclerosis	5.01e-05	0.00153	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Betamethasone—multiple sclerosis	5e-05	0.000632	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Dexamethasone—multiple sclerosis	5e-05	0.000632	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	4.99e-05	0.00152	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	4.99e-05	0.00152	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Triamcinolone—multiple sclerosis	4.97e-05	0.000628	CcSEcCtD
Levonorgestrel—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.96e-05	0.000626	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—ZFP36L1—multiple sclerosis	4.94e-05	0.00151	CbGpPWpGaD
Levonorgestrel—Vertigo—Methotrexate—multiple sclerosis	4.9e-05	0.000619	CcSEcCtD
Levonorgestrel—Urticaria—Betamethasone—multiple sclerosis	4.86e-05	0.000614	CcSEcCtD
Levonorgestrel—Urticaria—Dexamethasone—multiple sclerosis	4.86e-05	0.000614	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Prednisone—multiple sclerosis	4.85e-05	0.000613	CcSEcCtD
Levonorgestrel—Dizziness—Prednisolone—multiple sclerosis	4.85e-05	0.000613	CcSEcCtD
Levonorgestrel—ESR1—Gene Expression—PTBP1—multiple sclerosis	4.84e-05	0.00148	CbGpPWpGaD
Levonorgestrel—Asthenia—Triamcinolone—multiple sclerosis	4.84e-05	0.000611	CcSEcCtD
Levonorgestrel—Abdominal pain—Dexamethasone—multiple sclerosis	4.84e-05	0.000611	CcSEcCtD
Levonorgestrel—Abdominal pain—Betamethasone—multiple sclerosis	4.84e-05	0.000611	CcSEcCtD
Levonorgestrel—Body temperature increased—Dexamethasone—multiple sclerosis	4.84e-05	0.000611	CcSEcCtD
Levonorgestrel—Body temperature increased—Betamethasone—multiple sclerosis	4.84e-05	0.000611	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—multiple sclerosis	4.83e-05	0.00148	CbGpPWpGaD
Levonorgestrel—Asthenia—Methylprednisolone—multiple sclerosis	4.83e-05	0.00061	CcSEcCtD
Levonorgestrel—Insomnia—Prednisone—multiple sclerosis	4.82e-05	0.000609	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	4.78e-05	0.00146	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—STAT3—multiple sclerosis	4.77e-05	0.00146	CbGpPWpGaD
Levonorgestrel—Pruritus—Triamcinolone—multiple sclerosis	4.77e-05	0.000603	CcSEcCtD
Levonorgestrel—AR—Gene Expression—HNRNPA1—multiple sclerosis	4.76e-05	0.00146	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—U2AF2—multiple sclerosis	4.76e-05	0.00146	CbGpPWpGaD
Levonorgestrel—Cough—Methotrexate—multiple sclerosis	4.76e-05	0.000602	CcSEcCtD
Levonorgestrel—Pruritus—Methylprednisolone—multiple sclerosis	4.76e-05	0.000602	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.75e-05	0.00145	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Prednisone—multiple sclerosis	4.69e-05	0.000593	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—LINGO1—multiple sclerosis	4.69e-05	0.00143	CbGpPWpGaD
Levonorgestrel—Chest pain—Methotrexate—multiple sclerosis	4.64e-05	0.000587	CcSEcCtD
Levonorgestrel—Myalgia—Methotrexate—multiple sclerosis	4.64e-05	0.000587	CcSEcCtD
Levonorgestrel—ESR1—ATF-2 transcription factor network—MAPK1—multiple sclerosis	4.64e-05	0.00142	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Prednisone—multiple sclerosis	4.63e-05	0.000585	CcSEcCtD
Levonorgestrel—Rash—Prednisolone—multiple sclerosis	4.62e-05	0.000584	CcSEcCtD
Levonorgestrel—Dermatitis—Prednisolone—multiple sclerosis	4.62e-05	0.000584	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	4.61e-05	0.000583	CcSEcCtD
Levonorgestrel—Diarrhoea—Methylprednisolone—multiple sclerosis	4.6e-05	0.000582	CcSEcCtD
Levonorgestrel—Fatigue—Prednisone—multiple sclerosis	4.59e-05	0.000581	CcSEcCtD
Levonorgestrel—Headache—Prednisolone—multiple sclerosis	4.59e-05	0.00058	CcSEcCtD
Levonorgestrel—Discomfort—Methotrexate—multiple sclerosis	4.59e-05	0.00058	CcSEcCtD
Levonorgestrel—Constipation—Prednisone—multiple sclerosis	4.55e-05	0.000576	CcSEcCtD
Levonorgestrel—Dizziness—Triamcinolone—multiple sclerosis	4.46e-05	0.000563	CcSEcCtD
Levonorgestrel—Dizziness—Methylprednisolone—multiple sclerosis	4.45e-05	0.000562	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—MYC—multiple sclerosis	4.45e-05	0.00136	CbGpPWpGaD
Levonorgestrel—Infection—Methotrexate—multiple sclerosis	4.42e-05	0.000559	CcSEcCtD
Levonorgestrel—Asthenia—Betamethasone—multiple sclerosis	4.39e-05	0.000555	CcSEcCtD
Levonorgestrel—Asthenia—Dexamethasone—multiple sclerosis	4.39e-05	0.000555	CcSEcCtD
Levonorgestrel—Nervous system disorder—Methotrexate—multiple sclerosis	4.37e-05	0.000552	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Prednisone—multiple sclerosis	4.36e-05	0.000551	CcSEcCtD
Levonorgestrel—Nausea—Prednisolone—multiple sclerosis	4.35e-05	0.00055	CcSEcCtD
Levonorgestrel—Pruritus—Betamethasone—multiple sclerosis	4.33e-05	0.000547	CcSEcCtD
Levonorgestrel—Pruritus—Dexamethasone—multiple sclerosis	4.33e-05	0.000547	CcSEcCtD
Levonorgestrel—Skin disorder—Methotrexate—multiple sclerosis	4.32e-05	0.000547	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—PGR—multiple sclerosis	4.31e-05	0.00132	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Methotrexate—multiple sclerosis	4.3e-05	0.000544	CcSEcCtD
Levonorgestrel—Vomiting—Triamcinolone—multiple sclerosis	4.29e-05	0.000542	CcSEcCtD
Levonorgestrel—Vomiting—Methylprednisolone—multiple sclerosis	4.28e-05	0.000541	CcSEcCtD
Levonorgestrel—Rash—Triamcinolone—multiple sclerosis	4.25e-05	0.000537	CcSEcCtD
Levonorgestrel—Dermatitis—Triamcinolone—multiple sclerosis	4.25e-05	0.000537	CcSEcCtD
Levonorgestrel—Anorexia—Methotrexate—multiple sclerosis	4.24e-05	0.000536	CcSEcCtD
Levonorgestrel—Rash—Methylprednisolone—multiple sclerosis	4.24e-05	0.000536	CcSEcCtD
Levonorgestrel—Dermatitis—Methylprednisolone—multiple sclerosis	4.24e-05	0.000536	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—MYC—multiple sclerosis	4.24e-05	0.00129	CbGpPWpGaD
Levonorgestrel—Urticaria—Prednisone—multiple sclerosis	4.23e-05	0.000535	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—TGFB1—multiple sclerosis	4.23e-05	0.00129	CbGpPWpGaD
Levonorgestrel—Headache—Triamcinolone—multiple sclerosis	4.22e-05	0.000534	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—STAT3—multiple sclerosis	4.22e-05	0.00129	CbGpPWpGaD
Levonorgestrel—Headache—Methylprednisolone—multiple sclerosis	4.21e-05	0.000533	CcSEcCtD
Levonorgestrel—Body temperature increased—Prednisone—multiple sclerosis	4.21e-05	0.000532	CcSEcCtD
Levonorgestrel—Abdominal pain—Prednisone—multiple sclerosis	4.21e-05	0.000532	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—SRM—multiple sclerosis	4.2e-05	0.00128	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Dexamethasone—multiple sclerosis	4.18e-05	0.000529	CcSEcCtD
Levonorgestrel—Diarrhoea—Betamethasone—multiple sclerosis	4.18e-05	0.000529	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—MAPK1—multiple sclerosis	4.14e-05	0.00127	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—MYC—multiple sclerosis	4.14e-05	0.00126	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—TGFB1—multiple sclerosis	4.13e-05	0.00126	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.07e-05	0.00124	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TAGAP—multiple sclerosis	4.06e-05	0.00124	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	4.06e-05	0.000513	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—CD80—multiple sclerosis	4.05e-05	0.00124	CbGpPWpGaD
Levonorgestrel—Dizziness—Betamethasone—multiple sclerosis	4.04e-05	0.000511	CcSEcCtD
Levonorgestrel—Dizziness—Dexamethasone—multiple sclerosis	4.04e-05	0.000511	CcSEcCtD
Levonorgestrel—Insomnia—Methotrexate—multiple sclerosis	4.03e-05	0.000509	CcSEcCtD
Levonorgestrel—Nausea—Triamcinolone—multiple sclerosis	4e-05	0.000506	CcSEcCtD
Levonorgestrel—Nausea—Methylprednisolone—multiple sclerosis	4e-05	0.000505	CcSEcCtD
Levonorgestrel—Dyspnoea—Methotrexate—multiple sclerosis	3.97e-05	0.000502	CcSEcCtD
Levonorgestrel—Somnolence—Methotrexate—multiple sclerosis	3.96e-05	0.0005	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—VDR—multiple sclerosis	3.95e-05	0.00121	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Prednisone—multiple sclerosis	3.92e-05	0.000496	CcSEcCtD
Levonorgestrel—Dyspepsia—Methotrexate—multiple sclerosis	3.92e-05	0.000495	CcSEcCtD
Levonorgestrel—CYP19A1—Biological oxidations—POMC—multiple sclerosis	3.9e-05	0.00119	CbGpPWpGaD
Levonorgestrel—Vomiting—Dexamethasone—multiple sclerosis	3.89e-05	0.000492	CcSEcCtD
Levonorgestrel—Vomiting—Betamethasone—multiple sclerosis	3.89e-05	0.000492	CcSEcCtD
Levonorgestrel—Decreased appetite—Methotrexate—multiple sclerosis	3.87e-05	0.000489	CcSEcCtD
Levonorgestrel—Rash—Betamethasone—multiple sclerosis	3.86e-05	0.000488	CcSEcCtD
Levonorgestrel—Rash—Dexamethasone—multiple sclerosis	3.86e-05	0.000488	CcSEcCtD
Levonorgestrel—Dermatitis—Dexamethasone—multiple sclerosis	3.85e-05	0.000487	CcSEcCtD
Levonorgestrel—Dermatitis—Betamethasone—multiple sclerosis	3.85e-05	0.000487	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.84e-05	0.000486	CcSEcCtD
Levonorgestrel—Fatigue—Methotrexate—multiple sclerosis	3.84e-05	0.000485	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—MAPK1—multiple sclerosis	3.83e-05	0.00117	CbGpPWpGaD
Levonorgestrel—Headache—Betamethasone—multiple sclerosis	3.83e-05	0.000484	CcSEcCtD
Levonorgestrel—Headache—Dexamethasone—multiple sclerosis	3.83e-05	0.000484	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—PABPC1—multiple sclerosis	3.83e-05	0.00117	CbGpPWpGaD
Levonorgestrel—Asthenia—Prednisone—multiple sclerosis	3.82e-05	0.000483	CcSEcCtD
Levonorgestrel—Pain—Methotrexate—multiple sclerosis	3.81e-05	0.000481	CcSEcCtD
Levonorgestrel—Pruritus—Prednisone—multiple sclerosis	3.77e-05	0.000476	CcSEcCtD
Levonorgestrel—AR—Gene Expression—ZFP36L1—multiple sclerosis	3.76e-05	0.00115	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—MAPK1—multiple sclerosis	3.71e-05	0.00113	CbGpPWpGaD
Levonorgestrel—SRD5A1—nervous system—multiple sclerosis	3.69e-05	0.109	CbGeAlD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	3.68e-05	0.00113	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—HNRNPA1—multiple sclerosis	3.67e-05	0.00112	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—U2AF2—multiple sclerosis	3.67e-05	0.00112	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Prednisone—multiple sclerosis	3.64e-05	0.000461	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Methotrexate—multiple sclerosis	3.64e-05	0.00046	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	3.63e-05	0.00111	CbGpPWpGaD
Levonorgestrel—Nausea—Betamethasone—multiple sclerosis	3.63e-05	0.000459	CcSEcCtD
Levonorgestrel—Nausea—Dexamethasone—multiple sclerosis	3.63e-05	0.000459	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—APOE—multiple sclerosis	3.57e-05	0.00109	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—IL6—multiple sclerosis	3.57e-05	0.00109	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—S1PR1—multiple sclerosis	3.55e-05	0.00109	CbGpPWpGaD
Levonorgestrel—SRD5A1—central nervous system—multiple sclerosis	3.55e-05	0.105	CbGeAlD
Levonorgestrel—Urticaria—Methotrexate—multiple sclerosis	3.54e-05	0.000447	CcSEcCtD
Levonorgestrel—Dizziness—Prednisone—multiple sclerosis	3.52e-05	0.000445	CcSEcCtD
Levonorgestrel—Body temperature increased—Methotrexate—multiple sclerosis	3.52e-05	0.000445	CcSEcCtD
Levonorgestrel—Abdominal pain—Methotrexate—multiple sclerosis	3.52e-05	0.000445	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—RPL5—multiple sclerosis	3.46e-05	0.00106	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—GPC5—multiple sclerosis	3.46e-05	0.00106	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—TYK2—multiple sclerosis	3.42e-05	0.00105	CbGpPWpGaD
Levonorgestrel—Vomiting—Prednisone—multiple sclerosis	3.39e-05	0.000428	CcSEcCtD
Levonorgestrel—Rash—Prednisone—multiple sclerosis	3.36e-05	0.000425	CcSEcCtD
Levonorgestrel—Dermatitis—Prednisone—multiple sclerosis	3.36e-05	0.000424	CcSEcCtD
Levonorgestrel—Headache—Prednisone—multiple sclerosis	3.34e-05	0.000422	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—PGR—multiple sclerosis	3.32e-05	0.00101	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Methotrexate—multiple sclerosis	3.28e-05	0.000415	CcSEcCtD
Levonorgestrel—Asthenia—Methotrexate—multiple sclerosis	3.19e-05	0.000404	CcSEcCtD
Levonorgestrel—Nausea—Prednisone—multiple sclerosis	3.16e-05	0.0004	CcSEcCtD
Levonorgestrel—Pruritus—Methotrexate—multiple sclerosis	3.15e-05	0.000398	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL6—multiple sclerosis	3.11e-05	0.000951	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—POMC—multiple sclerosis	3.07e-05	0.000938	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Methotrexate—multiple sclerosis	3.05e-05	0.000385	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—RGS1—multiple sclerosis	3.02e-05	0.000923	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—VDR—multiple sclerosis	3.01e-05	0.000919	CbGpPWpGaD
Levonorgestrel—Testosterone—ALB—multiple sclerosis	2.99e-05	0.00859	CrCbGaD
Levonorgestrel—CYP19A1—Metabolism—CYP24A1—multiple sclerosis	2.96e-05	0.000905	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP27B1—multiple sclerosis	2.96e-05	0.000905	CbGpPWpGaD
Levonorgestrel—Dizziness—Methotrexate—multiple sclerosis	2.94e-05	0.000372	CcSEcCtD
Levonorgestrel—AR—Gene Expression—PABPC1—multiple sclerosis	2.92e-05	0.000892	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	2.9e-05	0.000888	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—ZFP36L1—multiple sclerosis	2.9e-05	0.000886	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.9e-05	0.000885	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—GPR65—multiple sclerosis	2.86e-05	0.000875	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—IL6—multiple sclerosis	2.85e-05	0.000871	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	2.84e-05	0.000868	CbGpPWpGaD
Levonorgestrel—Vomiting—Methotrexate—multiple sclerosis	2.83e-05	0.000358	CcSEcCtD
Levonorgestrel—SRD5A1—brain—multiple sclerosis	2.82e-05	0.0837	CbGeAlD
Levonorgestrel—Rash—Methotrexate—multiple sclerosis	2.81e-05	0.000355	CcSEcCtD
Levonorgestrel—Dermatitis—Methotrexate—multiple sclerosis	2.8e-05	0.000354	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—ALB—multiple sclerosis	2.8e-05	0.000855	CbGpPWpGaD
Levonorgestrel—Headache—Methotrexate—multiple sclerosis	2.79e-05	0.000353	CcSEcCtD
Levonorgestrel—ESR1—Signaling Pathways—LINGO1—multiple sclerosis	2.75e-05	0.000841	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GPC5—multiple sclerosis	2.71e-05	0.000828	CbGpPWpGaD
Levonorgestrel—Nausea—Methotrexate—multiple sclerosis	2.64e-05	0.000334	CcSEcCtD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.64e-05	0.000807	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—TNF—multiple sclerosis	2.64e-05	0.000806	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—RPL5—multiple sclerosis	2.63e-05	0.000804	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL13—multiple sclerosis	2.62e-05	0.0008	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCR1—multiple sclerosis	2.62e-05	0.0008	CbGpPWpGaD
Levonorgestrel—SHBG—brainstem—multiple sclerosis	2.56e-05	0.0761	CbGeAlD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	2.5e-05	0.000764	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	2.45e-05	0.000747	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.41e-05	0.000735	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.4e-05	0.000734	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TAGAP—multiple sclerosis	2.39e-05	0.000729	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.35e-05	0.00072	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—VDR—multiple sclerosis	2.32e-05	0.000708	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PABPC1—multiple sclerosis	2.25e-05	0.000687	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—RRM1—multiple sclerosis	2.24e-05	0.000686	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.24e-05	0.000685	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	2.24e-05	0.000684	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	2.19e-05	0.000669	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—MAPK1—multiple sclerosis	2.18e-05	0.000665	CbGpPWpGaD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.14e-05	0.000654	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL6—multiple sclerosis	2.13e-05	0.00065	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—S1PR1—multiple sclerosis	2.08e-05	0.000637	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PGR—multiple sclerosis	2.07e-05	0.000633	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—RPL5—multiple sclerosis	2.03e-05	0.00062	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GPC5—multiple sclerosis	2.03e-05	0.00062	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—VDR—multiple sclerosis	1.9e-05	0.000581	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCL3—multiple sclerosis	1.87e-05	0.00057	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.85e-05	0.000567	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.85e-05	0.000565	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.81e-05	0.000554	CbGpPWpGaD
Levonorgestrel—ESR1—brainstem—multiple sclerosis	1.81e-05	0.0536	CbGeAlD
Levonorgestrel—PGR—Signaling Pathways—PTGER4—multiple sclerosis	1.8e-05	0.000549	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RGS1—multiple sclerosis	1.77e-05	0.000542	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.74e-05	0.000532	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCR3—multiple sclerosis	1.73e-05	0.00053	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.73e-05	0.000528	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CD28—multiple sclerosis	1.72e-05	0.000525	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCR2—multiple sclerosis	1.69e-05	0.000516	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GPR65—multiple sclerosis	1.68e-05	0.000513	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—IL6—multiple sclerosis	1.67e-05	0.000511	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PGR—multiple sclerosis	1.6e-05	0.000488	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—MYC—multiple sclerosis	1.57e-05	0.00048	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CNR1—multiple sclerosis	1.56e-05	0.000476	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCR1—multiple sclerosis	1.54e-05	0.00047	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL13—multiple sclerosis	1.54e-05	0.00047	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.5e-05	0.000457	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—VDR—multiple sclerosis	1.45e-05	0.000443	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL10—multiple sclerosis	1.4e-05	0.000428	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.36e-05	0.000417	CbGpPWpGaD
Levonorgestrel—SHBG—central nervous system—multiple sclerosis	1.29e-05	0.0384	CbGeAlD
Levonorgestrel—CYP19A1—Metabolism—BCHE—multiple sclerosis	1.29e-05	0.000394	CbGpPWpGaD
Levonorgestrel—SHBG—cerebellum—multiple sclerosis	1.26e-05	0.0375	CbGeAlD
Levonorgestrel—CYP3A4—Metabolism—SRM—multiple sclerosis	1.23e-05	0.000375	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CD86—multiple sclerosis	1.23e-05	0.000375	CbGpPWpGaD
Levonorgestrel—PGR—nervous system—multiple sclerosis	1.21e-05	0.0359	CbGeAlD
Levonorgestrel—PGR—Signaling Pathways—CCL5—multiple sclerosis	1.21e-05	0.000369	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MYC—multiple sclerosis	1.2e-05	0.000365	CbGpPWpGaD
Levonorgestrel—PGR—central nervous system—multiple sclerosis	1.16e-05	0.0346	CbGeAlD
Levonorgestrel—AR—spinal cord—multiple sclerosis	1.14e-05	0.0339	CbGeAlD
Levonorgestrel—PGR—cerebellum—multiple sclerosis	1.14e-05	0.0338	CbGeAlD
Levonorgestrel—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.14e-05	0.000347	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SPP1—multiple sclerosis	1.12e-05	0.000342	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—VDR—multiple sclerosis	1.12e-05	0.000341	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCL3—multiple sclerosis	1.1e-05	0.000335	CbGpPWpGaD
Levonorgestrel—CYP19A1—nervous system—multiple sclerosis	1.09e-05	0.0323	CbGeAlD
Levonorgestrel—PGR—Signaling Pathways—CCR5—multiple sclerosis	1.09e-05	0.000332	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL2RA—multiple sclerosis	1.07e-05	0.000327	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTGER4—multiple sclerosis	1.05e-05	0.000322	CbGpPWpGaD
Levonorgestrel—CYP19A1—central nervous system—multiple sclerosis	1.05e-05	0.0311	CbGeAlD
Levonorgestrel—ESR1—Signaling Pathways—PGR—multiple sclerosis	1.04e-05	0.000317	CbGpPWpGaD
Levonorgestrel—SHBG—brain—multiple sclerosis	1.03e-05	0.0305	CbGeAlD
Levonorgestrel—ESR1—Signaling Pathways—CXCR3—multiple sclerosis	1.02e-05	0.000311	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CD28—multiple sclerosis	1.01e-05	0.000308	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCR2—multiple sclerosis	9.9e-06	0.000303	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—APOE—multiple sclerosis	9.89e-06	0.000302	CbGpPWpGaD
Levonorgestrel—AR—nervous system—multiple sclerosis	9.63e-06	0.0286	CbGeAlD
Levonorgestrel—ESR1—nervous system—multiple sclerosis	9.46e-06	0.0281	CbGeAlD
Levonorgestrel—AR—central nervous system—multiple sclerosis	9.27e-06	0.0275	CbGeAlD
Levonorgestrel—PGR—brain—multiple sclerosis	9.24e-06	0.0274	CbGeAlD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—multiple sclerosis	9.21e-06	0.000281	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CNR1—multiple sclerosis	9.14e-06	0.000279	CbGpPWpGaD
Levonorgestrel—ESR1—central nervous system—multiple sclerosis	9.11e-06	0.027	CbGeAlD
Levonorgestrel—PGR—Signaling Pathways—CD80—multiple sclerosis	8.94e-06	0.000273	CbGpPWpGaD
Levonorgestrel—ESR1—cerebellum—multiple sclerosis	8.9e-06	0.0264	CbGeAlD
Levonorgestrel—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	8.64e-06	0.000264	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	8.64e-06	0.000264	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—POMC—multiple sclerosis	8.5e-06	0.00026	CbGpPWpGaD
Levonorgestrel—CYP19A1—brain—multiple sclerosis	8.32e-06	0.0247	CbGeAlD
Levonorgestrel—PGR—Signaling Pathways—CCL2—multiple sclerosis	8.32e-06	0.000254	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL10—multiple sclerosis	8.23e-06	0.000251	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPC5—multiple sclerosis	7.91e-06	0.000242	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—APOE—multiple sclerosis	7.76e-06	0.000237	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—multiple sclerosis	7.56e-06	0.000231	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TYK2—multiple sclerosis	7.55e-06	0.000231	CbGpPWpGaD
Levonorgestrel—AR—brain—multiple sclerosis	7.36e-06	0.0219	CbGeAlD
Levonorgestrel—ESR1—brain—multiple sclerosis	7.23e-06	0.0215	CbGeAlD
Levonorgestrel—ESR1—Signaling Pathways—CD86—multiple sclerosis	7.2e-06	0.00022	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCL5—multiple sclerosis	7.08e-06	0.000216	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—POMC—multiple sclerosis	6.66e-06	0.000204	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SPP1—multiple sclerosis	6.56e-06	0.0002	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.55e-06	0.0002	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCR5—multiple sclerosis	6.38e-06	0.000195	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL2RA—multiple sclerosis	6.29e-06	0.000192	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL2—multiple sclerosis	6.28e-06	0.000192	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ALB—multiple sclerosis	6.07e-06	0.000186	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MMP9—multiple sclerosis	5.95e-06	0.000182	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—APOE—multiple sclerosis	5.81e-06	0.000177	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—multiple sclerosis	5.76e-06	0.000176	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—STAT3—multiple sclerosis	5.29e-06	0.000162	CbGpPWpGaD
Levonorgestrel—CYP3A4—nervous system—multiple sclerosis	5.28e-06	0.0157	CbGeAlD
Levonorgestrel—ESR1—Signaling Pathways—CD80—multiple sclerosis	5.25e-06	0.00016	CbGpPWpGaD
Levonorgestrel—CYP3A4—central nervous system—multiple sclerosis	5.08e-06	0.0151	CbGeAlD
Levonorgestrel—ESR1—Signaling Pathways—POMC—multiple sclerosis	4.99e-06	0.000152	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—multiple sclerosis	4.91e-06	0.00015	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TGFB1—multiple sclerosis	4.9e-06	0.00015	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCL2—multiple sclerosis	4.88e-06	0.000149	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAPK1—multiple sclerosis	4.81e-06	0.000147	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—multiple sclerosis	4.43e-06	0.000136	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TYK2—multiple sclerosis	4.43e-06	0.000135	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.76e-06	0.000115	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6—multiple sclerosis	3.69e-06	0.000113	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL2—multiple sclerosis	3.69e-06	0.000113	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MMP9—multiple sclerosis	3.49e-06	0.000107	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STAT3—multiple sclerosis	3.1e-06	9.48e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—multiple sclerosis	2.88e-06	8.81e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFB1—multiple sclerosis	2.88e-06	8.79e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAPK1—multiple sclerosis	2.82e-06	8.62e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—APOE—multiple sclerosis	2.26e-06	6.92e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6—multiple sclerosis	2.17e-06	6.62e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—POMC—multiple sclerosis	1.94e-06	5.94e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ALB—multiple sclerosis	1.77e-06	5.42e-05	CbGpPWpGaD
